689 related articles for article (PubMed ID: 25630504)
1. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
2. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
[TBL] [Abstract][Full Text] [Related]
3. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
[TBL] [Abstract][Full Text] [Related]
4. Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.
Nijsen MJMA; Wu F; Bansal L; Bradshaw-Pierce E; Chan JR; Liederer BM; Mettetal JT; Schroeder P; Schuck E; Tsai A; Xu C; Chimalakonda A; Le K; Penney M; Topp B; Yamada A; Spilker ME
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):135-146. PubMed ID: 29349875
[TBL] [Abstract][Full Text] [Related]
5. How do the top 12 pharmaceutical companies operate safety pharmacology?
Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
[TBL] [Abstract][Full Text] [Related]
6. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
7. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
Gieschke R; Steimer JL
Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
[TBL] [Abstract][Full Text] [Related]
8. Tools for predicting the PK/PD of therapeutic proteins.
Diao L; Meibohm B
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
[TBL] [Abstract][Full Text] [Related]
9. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/pharmacodynamics model-supported early drug development.
Chen B; Dong JQ; Pan WJ; Ruiz A
Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
[TBL] [Abstract][Full Text] [Related]
11. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
Block M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
[TBL] [Abstract][Full Text] [Related]
14. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
Zhao L; Shang EY; Sahajwalla CG
J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
[TBL] [Abstract][Full Text] [Related]
15. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
16. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic studies in drug product development.
Meibohm B; Derendorf H
J Pharm Sci; 2002 Jan; 91(1):18-31. PubMed ID: 11782894
[TBL] [Abstract][Full Text] [Related]
18. Automated analysis of routinely generated preclinical pharmacokinetic and pharmacodynamic data.
Lindhardt E; Gennemark P
J Bioinform Comput Biol; 2014 Jun; 12(3):1450010. PubMed ID: 24969748
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
[TBL] [Abstract][Full Text] [Related]
20. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
